Jul 26, 2017

Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress

Jun 29, 2017

Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.

Jun 27, 2017

Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego

Jun 1, 2017

Oncolytics Biotech® Announces Closing of Public Offering of Units

May 24, 2017

Oncolytics Biotech® Prices Public Offering of Units

May 23, 2017

Oncolytics Biotech® Announces Proposed Public Offering

May 23, 2017

Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017

May 17, 2017

Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers

May 8, 2017

Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer

May 5, 2017

Oncolytics Biotech® Inc. Announces 2017 First Quarter Results